Insights

ResApp (ASX:RAP) share price surges 5% on new agreement

The ResApp Health Ltd (ASX: RAP) share price is 5% higher today following a new agreement. We take a closer look at what the company announced.
The post ResApp (ASX:RAP) share price surges 5% on new agreement appeared first on The Motley Fool Australia. –

ehealth

The ResApp Health Ltd (ASX: RAP) share price is racing higher in mid-morning trade. This comes after the company announced a new agreement to accelerate sales in ResAppDx.

At the time of writing, the digital health company’s shares are fetching for 5.4 cents apiece, up 5.8%.

New agreement to accelerate ResApp sales

ResApp shares are on the move today as investors are pleased with the company’s latest update.

In a statement to the ASX, ResApp advised it has entered into a non-exclusive distribution agreement with Ilara Health.

Founded in 2019, Ilara Health provides affordable diagnostic equipment and services to small clinics and pharmacies across Africa. The company specialises in artificial intelligence medical devices such as portable ultrasound and blood diagnostics for diabetes. The current opportunity represents a market of more than 500 million people who live on the sub-Saharan Africa continent.

The deal will see ResApp provide its software application ResAppDx to Ilara Health for acute respiratory disease diagnosis in Kenya. This follows a successful pilot test undertaken by Ilara Health using ResAppDx at five partner sites in the country.

ResAppDx is a smartphone-based acute respiratory diagnostic test that has been developed to diagnose a range of health issues. These include lower respiratory tract disease, croup, pneumonia, asthma/reactive airway disease exacerbation, COPD exacerbation and bronchiolitis.

At present, Ilara Health has partnerships with over 250 clinics across four of the largest cities in Kenya. In addition, the healthcare provider is seeking to expand into a new African market within the next 12 months. This provides ResApp with a lucrative opportunity should sales meet targets.

The agreement has an initial term of 3 years, with Ilara Health to promote, market and sell ResAppDx in Kenya. Should the collaboration become successful, the deal can be renewed for consecutive 12-months periods by both parties.

Management commentary

Ilara Health CEO and co-founder, Emilian Popa welcomed the partnership, saying:

We have been thrilled with the simplicity, ease of use and confidence that ResAppDx has instilled in clinicians and patients. We see significant benefits that ResAppDx offers our partner clinics across Kenya as a low-cost and accurate respiratory diagnostic test.

ResApp CEO and managing director, Dr Tony Keating went on to add:

We are pleased that Ilara has seen the considerable value that our important diagnostic support provides their customers. Importantly, the pilot evaluation demonstrated the benefits of ResAppDx in a face-to-face, in-clinic setting and in a country with high unmet need for such diagnostics.

We are confident, that with the learnings from this pilot, Ilara Health will be able to bring the value of ResAppDx to a broad range of clinics in Kenya for the benefit of many clinicians and patients.

ResApp share price summary

Despite today’s positive announcement, ResApp shares have failed to take off in 2020, down almost 40%. When looking over the past 12 months, the company’s shares have fallen close to 70%.

ResApp presides a market capitalisation of roughly $46 million, with approximately 859.1 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post ResApp (ASX:RAP) share price surges 5% on new agreement appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!